FSSAI Pulls Up Dr Reddy's, Nestle Over Celevida Weight-Loss Claims

FSSAI flagged Dr Reddy's and Nestle Health Science over Celevida marketing, citing claims that the product provides muscle-preservation support during GLP-1/GIP therapies used in weight-loss treatment. For healthtech and nutraceutical founders, regulatory scrutiny on weight-loss category claims is intensifying—expect stricter labeling and marketing guidelines as GLP-1 adoption accelerates in India.

Source: ET HealthWorld ↗